ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 528.90K | 561.00K | 612.50K | 783.60K | 743.80K |
| Depreciation & Amortization | 71.00K | 59.60K | 40.20K | 21.90K | 7.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 965.70K | 916.70K | 861.40K | 999.10K | 964.00K |
| Operating Income | -965.70K | -916.70K | -861.40K | -999.10K | -964.00K |
| Income Before Tax | -891.70K | -856.90K | -838.10K | -950.70K | -917.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.89 | -0.86 | -0.84 | -0.95 | -0.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -891.70K | -856.90K | -838.10K | -950.70K | -917.80K |
| EBIT | -965.70K | -916.70K | -861.40K | -999.10K | -964.00K |
| EBITDA | -935.20K | -887.40K | -841.00K | -986.90K | -956.20K |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 115.82M | 111.22M | 106.81M | 102.31M | 99.06M |
| Average Diluted Shares Outstanding | 115.82M | 111.22M | 106.81M | 102.31M | 99.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |